Apotex has launched a generic version of Merck’s Nasonex mometasone furoate nasal spray in the United States, the company said. In June 2012, A US District Court judge upheld a Merck patent on mometasone furoate (US Patent No. 6,127,353) but ruled that Apotex’s nasal spray did not infringe on that patent.
According to the FDA, the agency approved Apotex’s ANDA for the nasal spray on March 21, 2016.
Apotex CEO and President Jeremy Desai commented, “We are very pleased to make a more affordable version of this important allergy medicine available to the US public. Apotex is dedicated to bringing high quality versions of complex generic products to market, and we are delighted that these efforts will generate substantial savings for the US health care system. The amount of work required by all stakeholders to enable the launch of a first generic of this complexity cannot be overstated, and we appreciate the role of everyone involved, including the FDA who provided steady guidance throughout the development process.”
Nasonex sells for approximately $250 with a coupon in the US.
Read the Apotex press release.
